Article | May 2, 2022

Understanding Your Process Reliability: Compliance Considerations For Emergency-Use Delivery Systems

By Richard Motruk, Chief Operating Officer, Kymanox Corporation, Morrisville, North Carolina, and Nathan Blazei, Head of Quality, Kymanox Corporation, Morrisville, North Carolina

Compliance GettyImages-1212446127

Historically, auto-injectors have been the predominant method of delivery for therapeutics involved in emergency-use scenarios (e.g., epinephrine, naloxone, and similar). Auto-injectors are designed for self-administration, whereby patients have the convenience of receiving the injections in a non-clinical setting (e.g., home or office). Since auto-injectors automatically carry out the injection cycle once actuated, patient compliance is improved compared to manual delivery devices, such as syringes. This capability is particularly important for emergency treatments, as an auto-injector can reliably administer the necessary dose in high pressure situations, whereas more manual delivery devices could be prone to user error and lead to drastic outcomes for the patient. Because auto-injectors are typically the delivery device of choice for emergency medications, they come with increased scrutiny from regulatory bodies regarding their safety and effectiveness.

This article reviews the FDA reliability requirement for auto-injectors and how to overcome the significant challenge for developers and manufacturers to meet compliance requirements.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader